Health Economics & Outcomes Research (HEOR)

We provide insights and analysis on potential market size and the design of rigorous economic evaluations, such as clinical studies and cost-effectiveness analysis.

Litigation Support & Policy Analysis (LSPA)

Our health economics methods support a wide range of healthcare litigation and health policy analyses, including expert services and testimony.

About

Health Economics & Outcomes Research

Led by Director and Principal Andrew Briggs, DPhil, and CEO John Schneider, PhD, AHE researchers and consultants have extensive knowledge and experience in the field of health economics and outcomes research (HEOR). These services include a wide variety of offerings across the product development continuum. In the early stages of development, we provide insights and analysis on potential market size and the design of rigorous economic evaluations, such as clinical studies and cost-effectiveness analysis.

About

Litigation Support & Policy Analysis (LSPA)

We bring rigorous health economics methodology to the complexities of health care litigation and policy analysis. Led by Director Cara Scheibling and CEO John Schneider, PhD, AHE researchers and consultants have extensive knowledge and experience providing health economics analysis, advice and testimony in support of a wide range of healthcare litigation and policy applications. Areas of expertise are listed below, and include substantial depth in a wide range of litigation, regulatory, and policy areas.

News

  • Avalon Health Economics will be at ISPOR Copenhagen 2019
    October 16, 2019
    Avalon Health Economics Will Be At ISPOR Copenhage...
    Avalon Health Economics will be at ISPOR Copenhagen November 2nd-6th. Let us know if you will be there and want to set up a meeting! For more information, please visit the ISPOR website.

    CONTINUE READING...
  • September 16, 2019
    New HEOR Publication: Monitoring Technology for Se...
    Economic evaluation of passive monitoring technology for seniors 2019 By John E. Schneider,  Jacie Cooper. Cara Scheibling, and Anjani Parikh Abstract: By 2050, the global population of persons...

    CONTINUE READING...
  • August 27, 2019
    Avalon & Oberender Enter a New Collaboration
        Avalon Health Economics has entered into a collaborative agreement with Oberender, a leading global healthcare management consultancy based in Germany.  The agreement allows Av...

    CONTINUE READING...
  • July 17, 2019
    Using Payer Research to Assess Medical Device Mark...
      This blog is written by  John Schneider, PhD, Sabrina Chmelir, Jacie Cooper, and Shawn Davies, MA Advances in technological innovation and access to capital have recently resulted in a wave o...

    CONTINUE READING...
  • June 20, 2019
    Optometry’s Essential and Expanding Role in Health...
    This research summary is written by John E. Schneider, PhD & Cara M. Scheibling   A two-decade drumbeat of bold, future-focused and entirely bi-partisan changes in U.S. state laws has ush...

    CONTINUE READING...
  • June 19, 2019
    Healthcare Use Cases for Blockchain Technology
    This blog was written by John Schneider, PhD, Katherine Dick, Cara Scheibling Recently, the crypto-currency company Bitcoin has been in the news, mainly for its combination of volatility in valuation...

    CONTINUE READING...
  • June 10, 2019
    Smoke, Mirrors, and Wild Geese :What Should Be the...
      Andrew Briggs, DPhil Chair of Health Economics, University of Glasgow, Glasgow UK. Senior Scientist, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Director and Principa...

    CONTINUE READING...
  • March 14, 2019
    Avalon Health Economics will be at ISPOR New Orlea...
    Avalon Health Economics will be at ISPOR New Orleans, May 18 through May 22. We will be engaged in our usual array of posters, podium presentations, and short courses. If you are planning on attending...

    CONTINUE READING...
  • December 26, 2018
    Avalon Health Economics Collaborates with Acaster-...
    Avalon Health Economics is happy to announce an exciting new collaboration with the London-based Acaster-Lloyd Consulting, Ltd. Acaster-Lloyd, led by Sarah Acaster and Andrew Lloyd, is a leader in the...

    CONTINUE READING...
  • September 28, 2018
    Avalon Health Economics will be at ISPOR Barcelona...
    Avalon Health Economics will be at ISPOR Barcelona, Nov. 10 through Nov. 14.  We will be engaged in our usual array of posters, podium presentations, and short courses.  If you are planning on attendi...

    CONTINUE READING...
  • December 1, 2017
    Avalon CEO John Schneider will be speaking at the ...
    Avalon CEO John Schneider will be speaking at the 4th Annual Conference on Health Outcomes, Data Communications, Market Access and Value-Based Contracting in Philadelphia, January 22-24, 2018.

    CONTINUE READING...
  • October 1, 2017
    Avalon CEO John Schneider will be presenting on th...
    Avalon CEO John Schneider will be presenting on the panel of "Blockchain Use-Cases, Brainstorm: Replacing the Middleman: Healthcare, Retail, Finance and More" at the Blockchain Economic Forum 2017 in ...

    CONTINUE READING...
  • October 1, 2017
    Avalon Health Economics at the 20th Annual Europea...
    In our work in health economics and outcomes research (HEOR) for the life sciences, including biotechnology, pharmaceuticals, and medical devices, we must maintain close ties with our colleagues and s...

    CONTINUE READING...
  • April 1, 2017
    AHE Presents: Symposium on Emerging Trends in U.S....
    Avalon Health Economics Presents: Symposium on Emerging Trends in U.S. Health Economic Evaluation: A Closer Look at the Role of Cost Effectiveness in U.S. Market Access Tuesday, May 9th at the Hy...

    CONTINUE READING...
  • February 22, 2017
    The Value of Biopharmaceutical Innovation in the U...
    There have been some negative reports recently regarding the pricing practices of some pharmaceutical companies. However, it is important to give at least equal consideration to the value derived from...

    CONTINUE READING...
  • December 7, 2016
    The Evolving Landscape of U.S. Payer Coverage Deci...
    Although there are a large number of public and private payers in the U.S., medical device and pharmaceutical manufacturers generally focus on two types of payers: (1) Medicare, which is administered ...

    CONTINUE READING...

Contact Us

Have a question or interested in learning more? Contact us!

Do NOT follow this link or you will be banned from the site!